VE303
Prevention of recurrent Clostridioides difficile infection (rCDI)
Key Facts
About Vedanta Biosciences
Vedanta Biosciences is a leader in the microbiome therapeutics space, advancing a pipeline of orally administered, defined bacterial consortia for gastrointestinal diseases. Its most advanced candidate, VE303, is in Phase 3 development for the prevention of recurrent C. difficile infection, with Phase 2 data recently published in *Nature Medicine*. The company's differentiated approach involves selecting specific bacterial strains to target the underlying microbial, metabolic, and immunologic imbalances of disease, positioning it to address significant unmet needs in areas like IBD and recurrent infections.
View full company profileAbout PureTech Health
PureTech Health is a Boston-based biotech studio that creates and funds separate companies around innovative scientific discoveries, de-risking development and capturing value through equity and royalties. Its model has proven exceptionally successful, boasting a 6x higher clinical success rate than the industry average and delivering three FDA-approved therapies. The company's strategy leverages a deep network of academic collaborators and seasoned leadership to build a diversified portfolio across immunology, neurology, and gastroenterology.
View full company profileTherapeutic Areas
Other Prevention of recurrent Clostridioides difficile infection (rCDI) Drugs
| Drug | Company | Phase |
|---|---|---|
| VOWST™ (SER-109) | Seres Therapeutics | Approved |